TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 94 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q1 2018. The put-call ratio across all filers is 0.42 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2017 | $2,921,000 | -7.9% | 463,700 | 0.0% | 0.15% | -15.6% |
Q3 2017 | $3,172,000 | -25.9% | 463,700 | -22.7% | 0.18% | -32.3% |
Q2 2017 | $4,278,000 | -22.4% | 600,000 | 0.0% | 0.27% | -27.1% |
Q1 2017 | $5,514,000 | +128.0% | 600,000 | 0.0% | 0.36% | +132.5% |
Q4 2016 | $2,418,000 | +5.2% | 600,000 | 0.0% | 0.16% | +12.1% |
Q3 2016 | $2,298,000 | -10.9% | 600,000 | 0.0% | 0.14% | -11.4% |
Q2 2016 | $2,580,000 | +84.7% | 600,000 | +330.7% | 0.16% | +125.7% |
Q4 2015 | $1,397,000 | +7.6% | 139,300 | -19.9% | 0.07% | -6.7% |
Q3 2015 | $1,298,000 | -90.6% | 174,000 | -40.0% | 0.08% | -89.9% |
Q2 2015 | $13,758,000 | +29.5% | 290,000 | 0.0% | 0.74% | -7.0% |
Q1 2015 | $10,626,000 | -7.7% | 290,000 | 0.0% | 0.80% | -36.4% |
Q4 2014 | $11,516,000 | +91.8% | 290,000 | -3.6% | 1.26% | +50.0% |
Q3 2014 | $6,003,000 | +47.9% | 300,900 | 0.0% | 0.84% | +51.8% |
Q2 2014 | $4,059,000 | +23.9% | 300,900 | 0.0% | 0.55% | +8.4% |
Q1 2014 | $3,277,000 | +150.9% | 300,900 | +211.5% | 0.51% | +26.6% |
Q4 2013 | $1,306,000 | – | 96,600 | – | 0.40% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 1,048,642 | $3,219,000 | 0.50% |
Virtus ETF Advisers LLC | 130,920 | $402,000 | 0.35% |
683 Capital Management, LLC | 600,000 | $1,842,000 | 0.16% |
Tekla Capital Management LLC | 859,322 | $2,638,000 | 0.10% |
DOW CHEMICAL CO /DE/ | 65,000 | $200,000 | 0.07% |
Alambic Investment Management, L.P. | 115,834 | $356,000 | 0.05% |
A.R.T. Advisors, LLC | 262,896 | $807,000 | 0.03% |
Candriam S.C.A. | 520,613 | $1,598,000 | 0.03% |
Man Group plc | 1,674,341 | $5,140,000 | 0.02% |
Baker Brothers Advisors | 935,000 | $2,870,000 | 0.02% |